This is the 19th volume, 12th issue of the EPVC’s monthly newsletter, published in December 2025. It serves as an official communication from the Egyptian Drug Authority (EDA) to healthcare professionals, regulators, and the public regarding drug safety, pharmacovigilance activities, and regulatory updates in Egypt.
Part 1: Optimizing Adult ADHD Treatment – Balancing Efficacy and Safety
A key highlight is the dissemination of a safety guide from New Zealand, focusing on medications for Adult Attention-Deficit/Hyperactivity Disorder (ADHD). This is crucial as adult ADHD diagnosis and treatment are increasing globally.
Medical Background: Adult ADHD is characterized by core symptoms of inattention, impulsivity, and executive dysfunction, leading to significant functional impairment. Unlike in children, inattention is often the predominant feature in adults.
Approved Medications & Mechanisms:
- Stimulants (Methylphenidate): Registered in Egypt. They primarily block the reuptake of dopamine and noradrenaline in the synaptic cleft, enhancing concentration and impulse control.
- Non-Stimulant (Atomoxetine): Also registered in Egypt. It is a selective noradrenaline reuptake inhibitor (NRI), often used when stimulants are contraindicated or ineffective.
- Lisdexamfetamine: A stimulant prodrug; not currently registered in Egypt.
Critical Safety Considerations for Prescribers:
The newsletter underscores a multi-system risk profile that necessitates careful patient assessment and monitoring:
| System | Risk | Clinical Action |
|---|---|---|
| Psychiatric | Exacerbation of comorbid disorders (e.g., psychosis, mania), suicidal ideation, tics, aggression. | Take detailed personal/family psychiatric history. Avoid in acute psychosis/suicidality. Monitor behavior, especially early in treatment. |
| Cardiovascular | Increased BP/HR; sudden death risk in those with structural cardiac abnormalities. | Pre-treatment cardiovascular assessment (history, BP, HR). Contraindicate in significant heart disease. Monitor BP/HR regularly. |
| Neurological | Lowered seizure threshold. | Use with caution in patients with seizure history. |
| Drug Interactions | Serotonin Syndrome risk when combined with SSRIs/SNRIs. | Monitor for symptoms (agitation, tremor, hyperthermia) if co-administration is necessary. |
| Other | Atomoxetine-specific: Risk of severe liver injury. Stimulant-specific: Potential for abuse/dependence. | Counsel patients on symptoms of hepatitis (jaundice, dark urine). Assess abuse potential before prescribing. |
Clinical Takeaway: Treating adult ADHD requires a holistic approach. Medication should be part of a comprehensive plan including psychological support. The choice between methylphenidate and atomoxetine must be individualized based on comorbidities, cardiovascular risk, and abuse potential.
Part 2: A Local Case Study – The Severe Consequences of Post-Thyroidectomy Non-Adherence
The newsletter presents a powerful Local Case Safety Report demonstrating the real-world impact of medication non-compliance.
Case Summary: A 50-year-old female with a history of total thyroidectomy presented with severe symptomatic hypocalcemia (Ca=5 mg/dL). Symptoms included carpopedal spasm, perioral tingling, inability to walk, and QT prolongation on ECG. The root cause was poor adherence to calcium supplementation and levothyroxine.
Medical Pathophysiology:
- Total Thyroidectomy: Removes the source of thyroid hormone (T4/T3) and often damages or removes the parathyroid glands, which regulate calcium homeostasis via Parathyroid Hormone (PTH).
- Levothyroxine Non-Adherence: Leads to hypothyroidism, causing fatigue, metabolic slowdown, and other complications.
- Calcium/Vitamin D Non-Adherence (with Parathyroid damage): Results in hypoparathyroidism, leading to hypocalcemia. Severe hypocalcemia increases neuromuscular excitability (causing spasms, tetany) and cardiac instability (prolonging the QT interval, risking fatal arrhythmias).
Recommendations for Healthcare Professionals:
- Proactive Prophylaxis: Initiate calcium and consider vitamin D immediately post-operatively, per protocol.
- Clear Discharge Planning: Provide written, simple dosing schedules. Educate on the critical importance of lifelong adherence.
- Administration Guidance: Instruct patients to take levothyroxine on an empty stomach and separate calcium doses by at least 4 hours to prevent impaired absorption of levothyroxine.
- Patient Support Tools: Encourage the use of pill organizers, phone reminders, or health apps.
- Monitoring: Educate patients to recognize early signs of hypocalcemia (tingling, muscle twitching) and seek immediate care.
Part 3: A National Safety Signal – Dicyclomine and Seizures in Breastfed Infants
This segment showcases EPVC’s proactive signal detection capabilities. A Safety Signal was identified linking maternal use of dicyclomine to seizures in breastfed infants.
Medical Background:
- Dicyclomine: An anticholinergic/antispasmodic used for irritable bowel syndrome. It crosses into breast milk.
- The Signal: The PVGA identified three serious domestic cases in VigiBase (ages 4-12 months) with a positive de-challenge (improvement after stopping exposure). A disproportionality analysis (Information Component) supported the signal.
Mechanism & Risk: Anticholinergic drugs can cross the blood-brain barrier. An infant’s immature blood-brain barrier and hepatic system make them particularly susceptible to central nervous system effects like seizures. The existing label contraindicated use in infants <6 months but lacked a strong warning for nursing mothers.
Regulatory Action & Recommendation: The EPVC has mandated risk minimization:
- Labeling Update: MAHs must update product information to contraindicate use during breastfeeding and in infants under 6 months.
- Healthcare Professional Awareness: Disseminate warnings to prescribers and pharmacists. Alternative antispasmodics should be considered for breastfeeding mothers.
Part 4: Strengthening Egypt’s Pharmacovigilance Culture
The newsletter outlines national efforts to embed PV into healthcare:
- “BE Vigilant” Initiative 2025: Aims to train PV focal points in hospitals to foster a reporting culture.
- Engagement with Academia: EPVC lectured on “Pharmacovigilance in Herbal Medicine” at Pharos University, emphasizing that natural does not equate to risk-free.
- VigiTest Competition: An annual challenge to test and improve healthcare professionals’ knowledge on PV concepts like de-challenge/re-challenge, enhancing the quality of ADR reporting.
